Your browser doesn't support javascript.
Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals.
Lechmere, Thomas; Snell, Luke B; Graham, Carl; Seow, Jeffrey; Shalim, Zayed A; Charalampous, Themoula; Alcolea-Medina, Adela; Batra, Rahul; Nebbia, Gaia; Edgeworth, Jonathan D; Malim, Michael H; Doores, Katie J.
  • Lechmere T; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, United Kingdom.
  • Snell LB; Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
  • Graham C; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, United Kingdom.
  • Seow J; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, United Kingdom.
  • Shalim ZA; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, United Kingdom.
  • Charalampous T; Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
  • Alcolea-Medina A; Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
  • Batra R; Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
  • Nebbia G; Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
  • Edgeworth JD; Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
  • Malim MH; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, United Kingdom.
  • Doores KJ; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, United Kingdom.
mBio ; 13(2): e0379821, 2022 04 26.
Article in English | MEDLINE | ID: covidwho-1745822
ABSTRACT
Numerous studies have shown that a prior SARS-CoV-2 infection can greatly enhance the antibody response to COVID-19 vaccination, with this so called "hybrid immunity" leading to greater neutralization breadth against SARS-CoV-2 variants of concern. However, little is known about how breakthrough infection (BTI) in COVID-19-vaccinated individuals will impact the magnitude and breadth of the neutralizing antibody response. Here, we compared neutralizing antibody responses between unvaccinated and COVID-19-double-vaccinated individuals (including both AZD1222 and BNT162b2 vaccinees) who have been infected with the Delta (B.1.617.2) variant. Rapid production of spike-reactive IgG was observed in the vaccinated group, providing evidence of effective vaccine priming. Overall, potent cross-neutralizing activity against current SARS-CoV-2 variants of concern was observed in the BTI group compared to the infection group, including neutralization of the Omicron (B.1.1.529) variant. This study provides important insights into population immunity where transmission levels remain high and in the context of new or emerging variants of concern. IMPORTANCE COVID-19 vaccines have been vital in controlling SARS-CoV-2 infections and reducing hospitalizations. However, breakthrough SARS-CoV-2 infections (BTI) occur in some vaccinated individuals. Here, we study how BTI impacts on the potency and the breadth of the neutralizing antibody response. We show that a Delta infection in COVID-19-vaccinated individuals provides potent neutralization against the current SARS-CoV-2 variants of concern, including the Omicron variant.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: MBio Year: 2022 Document Type: Article Affiliation country: Mbio.03798-21

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: MBio Year: 2022 Document Type: Article Affiliation country: Mbio.03798-21